What is Xeljanz used for?

( ARTG ) Ulcerative Colitis (UC),XELJANZ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.

What are the side effects of Xeljanz?

You can help ensure medicines are safe by reporting the side effects you experience. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Can Xeljanz be used during pregnancy?

( AHT ) For the active ingredient tofacitinib You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

What precautions should be taken with Xeljanz?

• Caution should be exercised in patients with history of hepatitis B or C, severe liver problems, serious infections, who are taking other medications, any allergy, during pregnancy and breastfeeding. • Patient may develop with increased risk of lymphoma, liver impairment and other cancers. • Monitor complete blood counts, liver enzyme and lipid levels regularly while taking this medication. • Avoid live vaccination while taking this medication.

What ATC class does Xeljanz belong to?

Xeljanz: ATC L04AF01. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Xeljanz

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

Xeljanz — Description, Dosage, Side Effects | PillsCard

USDailyMed:Tofacitinib AU:D L04AF01(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 3-{(3R,4R)-4-methyl-3-[(methyl)(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 477600-75-2 9926791 347827811 5677 DB08895Y 8102425Y 87LA6FU830 D09970Yas salt:D09783Y CHEBI:71200Y ChEMBL221959Y MI1 (PDBe,RCSB PDB) DTXSID90197271 Interactive image CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12 InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1Key:UJLAWZDWDVHW‍‍‍‍‍‍‍OW-YPMHNXCESA-N Tofacitinib, sold under the brandXeljanz, Neojanzamong others, is a medication used to treatrheumatoid arthritis,psoriatic arthritis,ankylosing spondylitis, polyarticular-coursejuvenile idiopathic arthritis, andulcerative colitis.It is ajanus kinase(JAK) inhibitor,discoveredanddevelopedby theNational Institutes of HealthandPfizer. Common side effects include diarrhea, headache, and high blood pressure.Serious side effects may include infections,cancer, andpulmonary embolism.In 2019, the safety committee of theEuropean Medicines Agencybegan a review of tofacitinib and recommended that doctors temporarily not prescribe the 10 mg twice-daily dose to people at high risk for pulmonary embolism.The U.S.Food and Drug Administration(FDA) also released warnings about the risk of blood clots.An important side effect of Jakinibs is serious bacterial, mycobacterial, fungal and viral infections. In thephase III trialsof tofacitinib amongopportunistic infections,pulmonary tuberculosis(TB) was reported in 3 cases all of which were initially negative upon screening for TB. It was approved for medical use in the United States in November 2012.The extended-release version was approved in February 2016.It is available as ageneric medication.

Xeljanz

User Reviews